Table A10Summary of the Incidence of Neoplasms in Female Heterozygous F1 p53+/− Mice in the 45-Week In Utero/Postnatal Gavage Study of AZTa

0/0/0 mg/kg80/40/80 mg/kg160/80/160 mg/kg240/120/240 mg/kg
Disposition Summary
Animals initially in study26272727
Early deaths
 Moribund11
 Natural death11
Survivors
 Died last week of study2325
 Terminal kill23232421
Animals examined microscopically26272727
Alimentary System
Esophagus(26)(27)(27)(27)
Intestine large, cecum(25)(27)(25)(24)
Intestine large, colon(26)(26)(27)(25)
Intestine large, rectum(25)(27)(27)(25)
Intestine small, ileum(25)(27)(25)(25)
Intestine small, jejunum(25)(27)(25)(25)
Liver(26)(27)(27)(27)
 Sarcoma1 (4%)
Mesentery(1)(0)(1)(1)
Pancreas(26)(27)(27)(26)
Salivary glands(26)(27)(26)(27)
Stomach, forestomach(26)(27)(27)(27)
 Squamous cell papilloma1 (4%)
Cardiovascular System
Heart(26)(27)(27)(26)
Endocrine System
Adrenal cortex(26)(27)(27)(26)
 Adenoma1 (4%)
Parathyroid gland(21)(22)(22)(22)
Pituitary gland(26)(27)(27)(27)
Thyroid gland(25)(27)(27)(26)
General Body System
Tissue NOS(0)(1)(0)(1)
 Thoracic, osteosarcoma1 (100%)
Genital System
Clitoral gland(25)(26)(26)(27)
Ovary(26)(27)(27)(26)
 Luteoma1 (4%)
Uterus(26)(27)(27)(27)
 Endometrium, polyp stromal1 (4%)
Vagina(25)(27)(27)(24)
Hematopoietic System
Bone marrow(26)(26)(26)(26)
 Sarcoma1 (4%)
Lymph node(1)(1)(0)(3)
Lymph node, mandibular(26)(27)(25)(26)
 Sarcoma1 (4%)
Lymph node, mesenteric(26)(26)(26)(27)
 Sarcoma1 (4%)
Spleen(26)(26)(27)(27)
 Sarcoma1 (4%)
Thymus(24)(26)(23)(27)
Integumentary System
Mammary gland(25)(26)(27)(27)
 Adenocarcinoma2 (7%)1 (4%)
Skin(26)(27)(27)(27)
 Fibrosarcoma1 (4%)
 Squamous cell carcinoma1 (4%)
Musculoskeletal System
Bone(0)(1)(0)(1)
 Cranium, osteoma1 (100%)
 Rib, osteosarcoma1 (100%)
Bone, femur(26)(27)(27)(27)
 Osteosarcoma1 (4%)2 (7%)1 (4%)
Skeletal muscle(26)(27)(27)(27)
Nervous System
Brain, brain stem(26)(27)(27)(27)
Brain, cerebrum(26)(27)(27)(27)
 Sarcoma1 (4%)
Peripheral nerve(2)(0)(0)(0)
Spinal cord(1)(0)(0)(0)
Respiratory System
Lung(26)(27)(26)(27)
 Alveolar/bronchiolar adenoma1 (4%)
 Osteosarcoma, metastatic, bone, femur1 (4%)
 Mediastinum, sarcoma1 (4%)
Nose(26)(27)(27)(27)
 Osteosarcoma1 (4%)
 Sarcoma1 (4%)
Special Senses System
Eye(25)(25)(26)(24)
Harderian gland(26)(27)(27)(25)
 Adenoma1 (4%)
Urinary System
Kidney(26)(27)(27)(27)
 Renal tubule, adenoma1 (4%)
Ureter(0)(0)(1)(0)
Urinary bladder(26)(27)(27)(26)
Systemic Lesions
Multiple organsb(26)(27)(27)(27)
 Histiocytic sarcoma1 (4%)1 (4%)
 Lymphoma malignant1 (4%)3 (11%)
 Mesothelioma malignant1 (4%)
Neoplasm Summary
Total animals with primary neoplasmsc4788
 Total primary neoplasms11798
Total animals with benign neoplasms1421
 Total benign neoplasms1421
Total animals with malignant neoplasms3367
 Total malignant neoplasms10377
Total animals with metastatic neoplasms1
 Total metastatic neoplasms1
a

Number of animals examined microscopically at the site and the number of animals with neoplasm

b

Number of animals with any tissue examined microscopically

c

Primary neoplasms: all neoplasms except metastatic neoplasms

From: APPENDIX A, SUMMARY OF LESIONS IN HETEROZYGOUS F1 p53+/− MICE IN THE IN UTERO/POSTNATAL GAVAGE STUDIES OF AZT

Cover of NTP Genetically Modified Model Report on the Toxicology and Carcinogenicity Studies of 3’-Azido-3’-Deoxythymidine (CASRN 30516-87-1) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (In Utero and Postnatal Gavage Study)
NTP Genetically Modified Model Report on the Toxicology and Carcinogenicity Studies of 3’-Azido-3’-Deoxythymidine (CASRN 30516-87-1) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (In Utero and Postnatal Gavage Study): NTP GMM 14 [Internet].
Leakey JEA, Allaben WT, Dunnick JK, et al.
Research Triangle Park (NC): National Toxicology Program; 2013 Oct.
Copyright Notice

This is a work of the US government and distributed under the terms of the Public Domain

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.